Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient.
Vincent CamusSydney DuboisStéphane LepretreFabrice JardinHervé TillyPublished in: Clinical case reports (2018)
Primary central nervous system lymphoma (PCNSL) remains a therapeutic challenge due to impaired drugs diffusion as a result of the blood-brain barrier and high risk of relapse. Patients with good performance status, chemo-sensitive disease, and eligible for autologous stem cell transplant (ASCT) may benefit from salvage therapy and therapeutic intensification that may allow long-term remission.
Keyphrases
- stem cells
- cell therapy
- diffuse large b cell lymphoma
- bone marrow
- disease activity
- cerebrospinal fluid
- platelet rich plasma
- ulcerative colitis
- case report
- photodynamic therapy
- rheumatoid arthritis
- systemic lupus erythematosus
- squamous cell carcinoma
- allogeneic hematopoietic stem cell transplantation
- locally advanced
- cancer therapy
- acute myeloid leukemia